VAD therapy 20/20: moving beyond the myopic view of a nascent therapy.
Abstract
The past five years have seen remarkable growth in the use of durable, continuous
flow left ventricular assist devices (LVAD) with associated improvements in mortality,
quality of life, functionality and end-organ function. To sustain the growth of this
important therapy, the LVAD community must now address key issues focused around the
costs of LVAD care, refined patient selection, and reducing complications associated
with this therapy. In this perspective piece, we discuss many of these issues.
Type
Journal articlePermalink
https://hdl.handle.net/10161/11078Published Version (Please cite this version)
10.3978/j.issn.2225-319X.2014.08.22Publication Info
(2014). VAD therapy 20/20: moving beyond the myopic view of a nascent therapy. Ann Cardiothorac Surg, 3(6). pp. 603-605. 10.3978/j.issn.2225-319X.2014.08.22. Retrieved from https://hdl.handle.net/10161/11078.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Adam David DeVore
Assistant Professor of Medicine
Adam D. DeVore, MD, MHS
Dr. DeVore is a cardiologist and Assistant Professor of Medicine in the Department
of Medicine, Division of Cardiology, at Duke University School of Medicine. His clinical
interests include caring for patients and families with heart failure, including those
with left ventricular assist devices and heart transplants. He is involved in and
leads multiple large studies of patients with heart failure at both Duke University
Medical Center and the
Carmelo Alessio Milano
Professor of Surgery
Alphabetical list of authors with Scholars@Duke profiles.
Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles